These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19132183)

  • 1. Another view on prasugrel.
    Calatzis A
    Thromb Haemost; 2009 Jan; 101(1):12-3. PubMed ID: 19132183
    [No Abstract]   [Full Text] [Related]  

  • 2. Prasugrel development - claims and achievements.
    Serebruany V; Shalito I; Kopyleva O
    Thromb Haemost; 2009 Jan; 101(1):14-22. PubMed ID: 19132184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-thienopyridine platelet response, cardiovascular outcomes, and personalized therapy: En attendant Godot.
    Tsimikas S; Leibundgut G
    JACC Cardiovasc Interv; 2010 Jun; 3(6):657-9. PubMed ID: 20630459
    [No Abstract]   [Full Text] [Related]  

  • 4. Bedside evaluation of thienopyridine antiplatelet therapy.
    Price MJ
    Circulation; 2009 May; 119(19):2625-32. PubMed ID: 19451364
    [No Abstract]   [Full Text] [Related]  

  • 5. Ischaemia versus bleeding: the art of clinical decision-making.
    Stone GW
    Lancet; 2009 Feb; 373(9665):695-6. PubMed ID: 19249613
    [No Abstract]   [Full Text] [Related]  

  • 6. The illusion of "optimal" platelet inhibition.
    Steinhubl SR
    JACC Cardiovasc Interv; 2012 Mar; 5(3):278-80. PubMed ID: 22440492
    [No Abstract]   [Full Text] [Related]  

  • 7. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.
    Motovska Z; Widimsky P
    Vasc Health Risk Manag; 2009; 5(1):475-81. PubMed ID: 19475783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet function analysis: at the edge of meaning.
    Oestreich JH; Smyth SS; Campbell CL
    Thromb Haemost; 2009 Feb; 101(2):217-9. PubMed ID: 19190799
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
    El Ghannudi S; Ohlmann P; Meyer N; Wiesel ML; Radulescu B; Chauvin M; Bareiss P; Gachet C; Morel O
    JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and clinical use of prasugrel and ticagrelor.
    Ahmad S; Storey RF
    Curr Pharm Des; 2012; 18(33):5240-60. PubMed ID: 22724412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prasugrel for the treatment of patients with acute coronary syndrome.
    Marzot F; Pengo V
    Vasc Health Risk Manag; 2009; 5(1):321-4. PubMed ID: 19436677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
    Tapp L; Shantsila E; Lip GY
    Circulation; 2010 Mar; 121(10):1169-71. PubMed ID: 20194888
    [No Abstract]   [Full Text] [Related]  

  • 14. Approaching an age of reason with antiplatelet therapy.
    Ajani AE; Lefkovits J
    Lancet; 2008 Apr; 371(9621):1315-6. PubMed ID: 18424309
    [No Abstract]   [Full Text] [Related]  

  • 15. New anti-platelet agents: the end of resistance?
    Kastrati A
    Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
    Behr T; Kuch B; Behr W; von Scheidt W
    Clin Res Cardiol; 2011 Oct; 100(10):907-14. PubMed ID: 21533581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Myocardial infarction: Role of new antiplatelet agents].
    Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
    Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
    Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
    Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prasugrel.
    Tantry US; Bliden KP; Gurbel PA
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1627-33. PubMed ID: 17107286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.